查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856235

Guillain-Barré二氏症候群市場依治療類型、產品類型、給藥途徑、通路和最終用戶分類－2025-2032年全球預測

Guillain-Barre Syndrome Market by Treatment Type, Product Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Guillain-Barré二氏症候群市場規模將達到 7.6144 億美元，複合年成長率為 1.69%。

關鍵市場統計數據
基準年 2024 6.6539億美元
預計年份：2025年 6.7651億美元
預測年份 2032 7.6144億美元
複合年成長率 (%) 1.69%

對塑造當代Guillain-Barré二氏症候群護理和治療路徑的臨床、治療和後勤動態進行了簡明扼要而又全面的說明。

Guillain-Barré二氏症候群(GBS) 起病急驟、臨床表現多樣，且需依賴免疫調節和支持性治療，因此對臨床醫生、製造商和醫療保健系統而言，它仍然是一個至關重要的領域。本執行摘要介紹了 GBS 的治療和護理現狀，總結了影響患者預後的臨床實踐模式、器械創新、分銷動態和服務提供模式。以下內容將 GBS 置於治療框架中，闡述了及時診斷和迅速啟動治療（包括靜脈注射免疫球蛋白和血漿置換）對於降低發病率和促進康復至關重要。

診斷通訊協定的進步、輸液方法的轉變以及居家照護日益成長的重要性正在重塑醫療服務路徑。這些變化與生技藥品和醫療設備監管要求的不斷變化以及影響產品供應和物流的供應鏈壓力交織在一起。摘要闡述了臨床實踐的融合點和仍存在的差距，並著重指出醫院和專科診所在提供持續、高品質醫療服務方面面臨的營運挑戰。透過概述治療模式、給藥途徑和分銷管道，本導言為後續的詳細分析奠定了堅實的基礎，使領導者能夠快速掌握影響策略和投資決策的結構性動態。

治療方法、服務模式、設備和遠端醫療的重大變革將徹底改變Guillain-Barré二氏症候群的診斷、治療和管理方式。

Guillain-Barré二氏症候群的治療格局正在經歷一場變革，這主要得益於技術創新、護理模式的革新以及藥物的改進。便於居家給藥的皮下注射免疫球蛋白製劑正日益普及，有助於縮短住院時間，並支持社區內照護的連續性。同時，血漿分離機的設計和一次性試劑套件的改進，使得血漿分離術更有效率、更安全，並能更好地適應包括專科門診中心在內的各種臨床環境。

除了設備和藥物的進步，遠端醫療和遠端監測也使得格林巴利症候群（GBS）患者的追蹤和復健協調更加有效。這些工具提高了神經科調整支持治療、管理自主神經併發症以及指導漸進式物理治療方案的能力。隨著標準化臨床方案和電生理檢測流程的廣泛應用，診斷速度也得到了提升，從而縮短了啟動治療的時間。最後，以患者為中心的服務模式，整合了家庭輸液服務、遠距復健和個案管理，正在重塑人們對復健軌蹟的預期和支付方的接受模式，從而影響著相關人員如何建構服務和分配資源。

2025 年定向關稅如何促使供應鏈重組、籌資策略改變以及考慮在國內生產用於治療Guillain-Barré二氏症候群的治療藥物和醫療設備。

美國2025年定向關稅的實施對Guillain-Barré二氏症候群常用治療方法和器械的供應鏈路線、籌資策略和成本結構產生了顯著影響。生技藥品和血漿衍生療法通常涉及複雜的國際採購和跨境供應，由於採購商和經銷商調整了供應商佈局和運輸路線以減輕關稅的影響，其物流也隨之發生了變化。這些調整促使醫療機構考慮供應商多元化和庫存策略，以維持急性神經系統疾病患者的治療連續性。

醫療設備製造商和經銷商正透過調整供應合約並考慮替代生產策略（例如近岸外包和提高國內組裝能力）來應對關稅帶來的風險。醫院系統和專科診所的採購團隊更加重視總到岸成本分析，該分析不僅考慮單位成本，還考慮關稅、運輸前置作業時間以及因改道運輸而可能面臨的監管審查。支付方和醫療系統正就價格調整和合約結構展開更積極的對話，以確保在不中斷以患者為中心的診療路徑的前提下，維持患者獲得必要的免疫療法和血液分離術服務。

在策略層面，監管聯絡團隊和貿易顧問在商業規劃中發揮著不可或缺的作用，因為製造商需要考慮關稅分類策略和關稅減免機會，例如在條件允許的情況下爭取關稅減免和優惠貿易制度。這些努力旨在穩定供應，確保關鍵治療藥物的及時供應，同時最大限度地降低跨境成本波動帶來的風險，避免影響急性免疫調節干預措施的營運準備。

一種細緻入微、以細分市場主導的視角，揭示了治療方式、產品類型、給藥途徑、分銷管道和最終用戶環境如何影響Guillain-Barré二氏症候群治療的提供。

細分市場分析揭示了臨床實踐、設備部署和分銷的交匯點，這些交匯點會影響醫療服務的可近性和提供。就治療類型而言，治療路徑以免疫調節和支持療法為主，包括皮質類固醇、靜脈注射免疫球蛋白、血漿置換以及一系列支持療法。對於靜脈注射免疫球蛋白，10% 和 5% 濃度的產品差異以及新興的皮下注射免疫球蛋白選擇，都會影響給藥流程和患者適用性。產品類型分為設備和藥品，其中設備包括血漿置換機和一次性試劑套件，藥品包括皮質類固醇和各種免疫球蛋白製劑，每種產品都需要獨特的採購和維護策略。

給藥途徑細分闡明了靜脈注射和皮下注射在臨床和操作層面的意義。靜脈注射包括中心靜脈和周邊靜脈途徑，而皮下注射正日益擴展到臨床輸液場所和家庭輸液模式，需要不同的醫護人員技能和監測通訊協定。通路細分考慮了醫院藥房、線上藥房和零售藥房途徑，每種途徑都有不同的庫存管理和監管合規要求。最終用戶細分區分了家庭醫療保健、醫院和專科診所。家庭醫療保健進一步細分為家庭輸液和遠端醫療服務，醫院分為私立和公立機構，專科診所分為神經科科診所和復健中心。綜合解讀這些細分，可以揭示在培訓、設備採購和物流的投資如何能夠最大程度地提高治療的及時性和復健服務的連續性，從而帶來最大的營運效益。

區域動態因素決定了美洲、歐洲、中東和非洲以及亞太地區Guillain-Barré二氏症候群藥物的可近性、上市時間和給藥模式。

區域動態顯著影響Guillain-Barré二氏症候群患者的生技藥品供應、器械部署和服務提供。在美洲，完善的血漿採集基礎設施和龐大的多醫院網路支持靜脈注射免疫球蛋白和血漿置換療法的廣泛應用。歐洲、中東和非洲則呈現出複雜的格局，各國醫療保健體系、血漿自給率以及生技藥品和醫療設備核准的法律規範各不相同。

亞太地區家庭輸液模式和本土生產能力投資正迅速成長，為傳統的醫院治療路徑提供了替代方案，並提高了社區皮下注射免疫球蛋白的使用率。儘管遠端醫療和遠端監測基礎設施正在所有地區擴展，但其與神經科護理的整合程度取決於數位健康政策、報銷系統和醫療服務提供者的準備。區域差異也會影響血漿置換等專業操作所需的人員配備以及康復資源的分配，進而影響康復路徑和跨境合作協議的設計，以確保供應的連續性。

多元化的公司概況正在影響Guillain-Barré二氏症候群的治療藥物供應、器械創新和綜合服務。

Guillain-Barré二氏症候群治療和器械生態系統中的主要企業包括血漿衍生生技藥品生產商、特種藥品生產商、專業血漿分離設備生產商和輸液服務提供者。現有的血漿分餾和免疫球蛋白生產商仍然是治療的核心，他們投資於產能、血漿捐贈者計畫和配方最佳化，以支持靜脈注射和皮下給藥。器械生產商正在改進血漿分離設備的設計，以提高安全性、便攜性和手術效率，同時提供可簡化設定並縮短手術時間的一次性產品。

藥物研發商和專業生產商正專注於提升製劑穩定性，並最佳化給藥方式，以支持門診和居家輸注。包括居家醫療機構和專業輸注合作夥伴在內的服務供應商，正在拓展其在患者教育、居家給藥培訓和遠端監測方面的能力，以支持患者的長期康復並減少住院次數。生產商、設備供應商和服務機構之間的合作日益普遍，其目標是將治療方法與物流和患者援助計劃相結合，從而提高患者的依從性和臨床療效。這些企業級措施體現了業界對臨床需求的正面回應，這些需求包括靈活的給藥途徑、可靠的供應保障以及更好的病患體驗。

為製造商、醫療保健提供者和支付方提供切實可行的策略行動，以增強供應鏈韌性，促進居家照護，並將創新與改善患者就醫路徑聯繫起來。

產業領導者應優先考慮幾項策略性舉措，以掌握臨床趨勢並保障醫療服務的連續性。首先，投資供應鏈多元化和血漿採購夥伴關係，以降低進口中斷和關稅波動帶來的風險。其次，加速皮下注射免疫球蛋白產品和以患者為中心的醫療器械的研發和監管申報，這些產品和器械能夠實現安全的居家給藥，並使產品設計與不斷發展的居家輸注和遠端醫療模式相適應。第三，加強與器械製造商和服務供應商的合作，開發捆綁式解決方案，簡化採購流程，並確保協調一致的培訓、維護和患者支援。

此外，我們應專注於遠端監測和遠端復健的數位基礎設施，以促進急性後期復原並降低再入院風險。我們應積極與支付者和醫療系統合作，建立基於價值的合約框架，充分考慮門診和居家照護模式的整體成本效益。最後，我們應將資源投入到血液分離和輸液護理人員的培養以及標準化臨床路徑的製定，以減少治療時間的差異並改善長期療效。這些措施將增強醫療系統的韌性，支持可擴展的照護模式，並提高治療方法和器材創新轉化為可衡量的患者獲益的可能性。

我們的研究結果和建議以透明的多來源研究途徑為支撐，該方法結合了專家訪談、臨床文獻綜述、設備和監管數據以及供應鏈分析。

本執行摘要所依據的研究整合了多方面的證據，以確保得出可靠且可操作的結論。關鍵資訊來源包括對神經病學和重症患者監護臨床專家、採購和供應鏈專業人員、設備技術人員以及家庭輸液服務負責人進行的結構化訪談。這些專家觀點與同行評審的臨床文獻系統評估、器械註冊資訊、生技藥品和器械監管申報文件以及衛生當局和專業協會發布的公開指南相結合，旨在檢驗臨床實踐模式和推廣應用的促進因素。

此分析方法結合了產品和服務屬性的比較評估和定性綜合分析，包括製劑特性、給藥物流和設備易用性。供應鏈分析考慮了採購佈局、物流路線和關稅風險情景，並評估了營運風險及應對方案。在可能的情況下，研究結果會從獨立資訊來源得到驗證，以減少偏差並支持所提出的建議。調查方法強調假設的透明度和對臨床及營運訊號的保守解讀，旨在為相關人員提供策略指導。

本文簡要概述了相關人員為改善Guillain-Barré二氏症候群可靠的以患者為中心的護理和康復路徑而必須應對的機會和營運挑戰。

總之，在免疫球蛋白、血液分離設備和數位健康工具等創新技術的推動下，Guillain-Barré二氏症候群的診療體係正朝著更靈活、以病人為中心的模式發展。這些變革為提高治療及時性、透過全面康復和遠端監測促進患者康復以及減少對長期住院的依賴提供了機會。然而，這項轉型也帶來了採購、品質保證和人才培育的複雜性，各機構必須積極應對。

相關人員協調產品開發與服務交付、實現供應來源多元化並投資於培訓和數位基礎設施，將更有利於將臨床創新轉化為可靠的病患療效。政策制定者和支付方應發揮作用，建構有利於醫療保健安全分散化的報銷機制和監管路徑。透過關注本摘要中強調的營運和策略考量，領導者可以減少獲得救命治療的差異，並改善Guillain-Barré二氏症候群患者的持續照護。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對補體抑制劑治療難治性Guillain-Barré二氏症候群的活性化臨床試驗正在進行中
  • 擴大遠端醫療和數位復健平台的使用，以支持格林巴利症候群患者的康復。
  • 對用於早期檢測Guillain-Barré二氏症候群的快速診斷檢測和生物標記組合的需求日益成長
  • 加強對疫苗接種Guillain-Barré二氏症候群，這將影響監管政策。
  • 引入家庭輸液服務進行靜脈注射免疫球蛋白治療，提高了患者的依從性。
  • 生物相似藥開發商針對高成本免疫球蛋白製劑（用於治療格林-巴利綜合症）進行策略性市場開發。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Guillain-Barré二氏症候群市場依治療類型分類

  • 皮質類固醇
  • 靜脈注射免疫球蛋白療法
    • 10%免疫球蛋白
    • 5%免疫球蛋白
    • 皮下注射免疫球蛋白
  • 血漿置換
  • 支持性護理

第9章Guillain-Barré二氏症候群市場（依產品類型分類）

  • 裝置
    • 血液分離機
    • 套件
  • 製藥
    • 皮質類固醇
    • 靜脈注射免疫球蛋白

第10章Guillain-Barré二氏症候群市場（依給藥途徑分類）

  • 靜脈注射
    • 中心靜脈給藥
    • 周邊靜脈給藥
  • 皮下注射
    • 臨床環境
    • 居家輸液

第11章Guillain-Barré二氏症候群市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Guillain-Barré二氏症候群市場（依最終用戶分類）

  • 家庭醫療保健
    • 居家輸液
    • 遠端醫療服務
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 神經科診所
    • 復健中心

第13章Guillain-Barré二氏症候群市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Guillain-Barré二氏症候群市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國Guillain-Barré二氏症候群市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Kedrion SpA
    • Biotest AG
    • LFB, Groupe Bioproduction
    • Sandoz International GmbH
    • Fresenius Kabi AG
    • Bio Products Laboratory Limited
Product Code: MRR-450A0628D980

The Guillain-Barre Syndrome Market is projected to grow by USD 761.44 million at a CAGR of 1.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 665.39 million
Estimated Year [2025] USD 676.51 million
Forecast Year [2032] USD 761.44 million
CAGR (%) 1.69%

A concise yet comprehensive orientation to the clinical, therapeutic, and logistical dynamics shaping contemporary Guillain-Barre syndrome care and treatment pathways

Guillain-Barre syndrome (GBS) remains a critical area of focus for clinicians, manufacturers, and health systems due to its acute onset, varied clinical presentation, and reliance on immunomodulatory therapies and supportive care. This executive summary introduces the therapeutic and care landscape, synthesizing clinical practice patterns, device innovations, distribution dynamics, and service delivery models that shape patient outcomes. The content that follows frames GBS within a treatment paradigm where timely diagnosis and rapid initiation of therapy, typically involving intravenous immunoglobulin or plasmapheresis, are essential to reduce morbidity and accelerate recovery.

Advances in diagnostic protocols, shifts in infusion modalities, and the growing importance of home-based care have reconfigured the care pathway. These changes intersect with evolving regulatory expectations for biologics and devices, as well as with supply-chain pressures that influence product availability and logistics. The summary highlights where clinical practice is converging and where gaps remain, drawing attention to the operational challenges hospitals and specialty clinics face in delivering consistent, high-quality care. By outlining therapeutic modalities, administration routes, and distribution channels, this introduction provides a cohesive foundation for the detailed analyses that follow, enabling leaders to quickly grasp the structural dynamics that will influence strategy and investment decisions.

Compelling shifts in therapies, service models, devices, and telehealth that are reshaping how Guillain-Barre syndrome is diagnosed, treated, and managed across care settings

The landscape for Guillain-Barre syndrome is undergoing transformative shifts driven by technological innovation, care model reconfiguration, and pharmacological refinement. There is growing momentum behind subcutaneous immunoglobulin formulations that facilitate home-based administration, reducing length of hospital stay and supporting continuity of care in community settings. Concurrently, improvements in apheresis machine design and disposable kits have made plasmapheresis procedures more efficient, safer, and adaptable to a wider range of clinical environments, including specialized outpatient centers.

In addition to device and formulation advances, telemedicine and remote monitoring are enabling more robust follow-up and rehabilitation coordination for patients recovering from GBS. These tools are enhancing neurologists' ability to titrate supportive therapies, manage autonomic complications, and guide progressive physical therapy regimens. Diagnostic speed is also improving through standardized clinical protocols and wider adoption of electrophysiological testing pathways, which together shorten time to treatment initiation. Finally, patient-centric service models that integrate home infusion services, tele-rehabilitation, and case management are reshaping expectations for recovery trajectories and payer coverage patterns, thereby influencing how stakeholders structure offerings and allocate resources.

How targeted 2025 tariff measures have compelled supply reconfiguration, procurement strategy changes, and domestic production considerations for therapies and devices used in Guillain-Barre syndrome care

The introduction of targeted tariff measures in the United States in 2025 has had a discernible effect on supply chain routing, procurement strategies, and cost structures for therapies and devices commonly used in Guillain-Barre syndrome care. Biologics and plasma-derived therapies, which are often subject to complex international sourcing and cross-border supply operations, experienced altered logistics as purchasers and distributors reassessed vendor footprints and transit routing to mitigate tariff exposure. These adjustments have prompted healthcare organizations to examine supplier diversification and inventory strategies to preserve continuity of care for acute neurological conditions.

Device manufacturers and distributors have responded by recalibrating supply agreements and considering alternative production strategies, such as nearshoring or increasing domestic assembly capacity, to reduce tariff-related vulnerability. For hospital systems and specialty clinics, procurement teams have placed greater emphasis on total landed cost analysis, taking into account not only unit pricing but also duties, transit lead times, and potential regulatory inspections associated with re-routed shipments. Payers and health systems have engaged in more active dialogue around pricing adjustments and contracting mechanisms to maintain access to essential immunotherapies and apheresis services without disrupting patient-centric care pathways.

At a strategic level, regulatory liaison teams and trade counsel have become more integral to commercial planning as manufacturers examine tariff mitigation measures, including tariff classification strategies and opportunities for duty drawback or preferential trade programs where available. These responses aim to stabilize supply and preserve timely delivery of critical therapies while minimizing exposure to volatile cross-border cost pressures that could otherwise impede operational readiness for acute immunomodulatory interventions.

A nuanced segmentation-driven view illuminating how treatment modalities, product types, administration routes, distribution channels, and end-user settings jointly shape delivery of Guillain-Barre syndrome care

Segmentation analysis clarifies where clinical practice, device deployment, and distribution intersect to influence access and care delivery. When considering treatment type, therapeutic pathways are dominated by immunomodulatory and supportive approaches such as corticosteroids, intravenous immunoglobulin, plasmapheresis, and a range of supportive therapies; within intravenous immunoglobulin, product differentiation between 10 percent and 5 percent concentrations as well as emerging subcutaneous immunoglobulin options affects administration logistics and patient suitability. Product-type segmentation separates devices from pharmaceuticals, with devices encompassing apheresis machines and disposable kits and pharmaceuticals encompassing corticosteroids and various immunoglobulin formulations, each requiring distinct procurement and maintenance strategies.

Route-of-administration segmentation highlights the clinical and operational implications of intravenous versus subcutaneous delivery; intravenous approaches include central venous and peripheral venous administration pathways, while subcutaneous delivery increasingly spans clinical infusion settings and home infusion models, necessitating different staffing competencies and monitoring protocols. Distribution-channel segmentation examines hospital pharmacy, online pharmacy, and retail pharmacy pathways, each creating distinct inventory management and regulatory compliance profiles. End-user segmentation differentiates home healthcare, hospitals, and specialty clinics, with home healthcare further subdividing into home infusion and telemedicine services, hospitals into private and public institutions, and specialty clinics into neurology clinics and rehabilitation centers. Interpreting these segments together reveals where investment in training, device procurement, and logistics yields the highest operational leverage to improve timeliness of therapy and continuity of rehabilitation services.

Regional dynamics that determine availability, adoption timing, and delivery models for Guillain-Barre syndrome therapies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence availability of biologics, device deployment, and service delivery for Guillain-Barre syndrome patients. In the Americas, established plasma collection infrastructures and large integrated hospital networks support broad access to intravenous immunoglobulin and apheresis services, while regional differences in reimbursement and outpatient infusion capacity shape where patients receive therapy and rehabilitation. Europe, Middle East & Africa present a complex mosaic driven by variations in national health systems, differing levels of plasma self-sufficiency, and regulatory frameworks that govern biologics and device approvals; these factors affect timelines for adoption of new formulations and device upgrades across public and private institutions.

Asia-Pacific exhibits rapid growth in home infusion models and investments in domestic manufacturing capacity, which are creating alternatives to traditional hospital-centric care pathways and increasing the adoption of subcutaneous immunoglobulin in community settings. Across all regions, infrastructure for telemedicine and remote monitoring is expanding, but its integration into neurology care varies with digital health policy, reimbursement mechanisms, and provider readiness. Regional differences also influence workforce availability for specialized procedures like plasmapheresis and the distribution of rehabilitation resources, thereby shaping recovery pathways and the design of cross-border collaboration agreements for supply continuity.

Profiles of the diverse set of companies shaping therapeutic supply, device innovation, and integrated service delivery for Guillain-Barre syndrome care

Leading companies involved in the therapeutic and device ecosystem for Guillain-Barre syndrome span plasma-derived biologics producers, specialty pharmaceutical manufacturers, device makers focused on apheresis systems, and providers of infusion services. Established plasma fractionators and immunoglobulin producers remain central to therapy supply, investing in production capacity, plasma donor programs, and formulation optimization to support intravenous and subcutaneous delivery options. Device manufacturers are advancing apheresis machine design to improve safety, portability, and procedural efficiency while supplying disposables that simplify set-up and reduce procedure time.

Pharmaceutical developers and specialty manufacturers are emphasizing formulation stability and user-friendly administration formats to support outpatient and home-based infusion. Service providers, including home healthcare agencies and specialty infusion partners, are expanding capabilities in patient education, training for home administration, and remote monitoring to support long-term recovery and reduce hospital utilization. Collaborations between manufacturers, device suppliers, and service organizations are increasingly common, aimed at integrating therapy delivery with logistics and patient support programs to enhance adherence and clinical outcomes. These company-level initiatives reflect an industry response to clinical demand for flexible administration pathways, robust supply reliability, and improved patient experience.

Practical and strategic actions for manufacturers, providers, and payers to strengthen supply resilience, enable home-based care, and translate innovation into improved patient pathways

Industry leaders should prioritize several strategic initiatives to capitalize on clinical trends and safeguard continuity of care. First, invest in diversification of supply chains and plasma sourcing partnerships to reduce vulnerability to import disruptions and tariff-related volatility. Second, accelerate development and regulatory submissions for subcutaneous immunoglobulin formulations and patient-centric devices that enable safe home administration, thereby aligning product design with the expanding home infusion and telemedicine models. Third, strengthen collaborations between device manufacturers and service providers to create bundled offerings that simplify procurement and ensure coordinated training, maintenance, and patient support.

Additionally, organizations should pursue targeted investments in digital infrastructure for remote monitoring and tele-rehabilitation to enhance post-acute recovery and reduce readmission risk. Engage proactively with payers and health systems to establish value-based contracting frameworks that recognize the total cost benefits of outpatient and home-based care models. Finally, dedicate resources to workforce training for apheresis and infusion nursing, and to the development of standardized clinical pathways that reduce variability in time-to-treatment and improve long-term outcomes. These actions will enhance resilience, support scalable care models, and increase the likelihood that innovations in therapies and devices translate into measurable patient benefit.

A transparent and multi-source research approach combining expert interviews, clinical literature review, device and regulatory data, and supply-chain analysis to underpin findings and recommendations

The research underpinning this executive summary integrates multiple evidence streams to ensure robust, actionable conclusions. Primary inputs include structured interviews with clinical specialists in neurology and critical care, procurement and supply-chain professionals, device engineers, and leaders of home infusion services. These expert perspectives were triangulated with a systematic review of peer-reviewed clinical literature, device registries, regulatory filings for biologics and devices, and publicly available guidance from health authorities and professional societies to validate clinical practice patterns and adoption drivers.

Analytical methods combined qualitative synthesis with comparative assessments of product and service attributes, including formulation characteristics, administration logistics, and device usability. Supply-chain analysis considered sourcing footprints, logistics pathways, and tariff exposure scenarios to evaluate operational risk and mitigation options. Wherever possible, findings were corroborated across independent sources to reduce bias and to provide a defensible basis for the recommendations offered. The methodology emphasizes transparency in assumptions and uses conservative interpretation of clinical and operational signals to inform strategic guidance for stakeholders.

A concise synthesis of opportunities and operational challenges that stakeholders must address to ensure reliable, patient-centered care and improved recovery pathways for Guillain-Barre syndrome

In conclusion, the care ecosystem for Guillain-Barre syndrome is evolving toward more flexible, patient-centered delivery models supported by innovations in immunoglobulin formulations, apheresis devices, and digital health tools. These changes offer opportunities to improve timeliness of therapy, facilitate recovery through integrated rehabilitation and remote monitoring, and reduce reliance on prolonged inpatient stays. However, this transition also introduces complexity in procurement, quality assurance, and workforce training that organizations must address proactively.

Stakeholders that align product development with service delivery, diversify supply sources, and invest in training and digital infrastructure will be better positioned to translate clinical innovations into reliable patient outcomes. Policymakers and payers have a role in enabling reimbursement structures and regulatory pathways that encourage safe decentralization of care. By attending to the operational and strategic considerations highlighted in this summary, leaders can reduce variability in access to lifesaving therapies and enhance the continuum of care for patients affected by Guillain-Barre syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing clinical trial activity for complement inhibitors targeting refractory Guillain-Barre syndrome
  • 5.2. Expanding use of telehealth and digital rehabilitation platforms to support post-GBS patient recovery
  • 5.3. Growing demand for rapid diagnostic assays and biomarker panels for early Guillain-Barre syndrome detection
  • 5.4. Heightened scrutiny of post-vaccination Guillain-Barre syndrome incidence influencing regulatory policies
  • 5.5. Emergence of home infusion services for intravenous immunoglobulin therapy improving patient adherence rates
  • 5.6. Strategic market entry by biosimilar developers targeting high-cost immunoglobulin products in GBS treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Guillain-Barre Syndrome Market, by Treatment Type

  • 8.1. Corticosteroids
  • 8.2. Intravenous Immunoglobulin
    • 8.2.1. 10% Immunoglobulin
    • 8.2.2. 5% Immunoglobulin
    • 8.2.3. Subcutaneous Immunoglobulin
  • 8.3. Plasmapheresis
  • 8.4. Supportive Therapies

9. Guillain-Barre Syndrome Market, by Product Type

  • 9.1. Devices
    • 9.1.1. Apheresis Machines
    • 9.1.2. Disposable Kits
  • 9.2. Pharmaceuticals
    • 9.2.1. Corticosteroids
    • 9.2.2. Intravenous Immunoglobulin

10. Guillain-Barre Syndrome Market, by Route Of Administration

  • 10.1. Intravenous
    • 10.1.1. Central Venous Administration
    • 10.1.2. Peripheral Venous Administration
  • 10.2. Subcutaneous
    • 10.2.1. Clinical Setting
    • 10.2.2. Home Infusion

11. Guillain-Barre Syndrome Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Guillain-Barre Syndrome Market, by End User

  • 12.1. Home Healthcare
    • 12.1.1. Home Infusion
    • 12.1.2. Telemedicine Services
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Specialty Clinics
    • 12.3.1. Neurology Clinics
    • 12.3.2. Rehabilitation Centers

13. Guillain-Barre Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Guillain-Barre Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Guillain-Barre Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Limited
    • 16.3.2. Grifols, S.A.
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Octapharma AG
    • 16.3.5. Kedrion S.p.A.
    • 16.3.6. Biotest AG
    • 16.3.7. LFB, Groupe Bioproduction
    • 16.3.8. Sandoz International GmbH
    • 16.3.9. Fresenius Kabi AG
    • 16.3.10. Bio Products Laboratory Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE